CD8A and neoplasm: As the therapies from tumor progression/regression inevitably vary, identification of key biomarkers such as circulating tumor DNA (ctDNA) concentrations, use of non-invasive biopsy for assessment of CD8+ and TIA1+ levels can aid therapy management (Ma et al., 2019).